Coya Therapeutics officially went public on December 29, 2022, pricing its initial public offering (IPO) on the Nasdaq Capital Market under the ticker symbol COYA. The clinical-stage biotechnology company raised capital to advance its proprietary regulatory T cell-enhancing therapeutic platforms targeting neuroinflammation and systemic autoimmune disorders.